^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20-targeted CAR-T immunotherapy

    Related drugs:
    5d
    A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=439, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2029 --> Jul 2041
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    7d
    CAR-T for R/R B-NHL (clinicaltrials.gov)
    P2, N=168, Completed, The First Affiliated Hospital of Soochow University | Unknown status --> Completed | N=10 --> 168
    Trial completion • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD22 (CD22 Molecule)
    |
    CAR-T CD19/CD20/CD22/CD30
    12d
    OSU-21170: Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=54, Recruiting, Sumithira Vasu | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells
    21d
    OSU-21170: Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=54, Recruiting, Sumithira Vasu | Trial completion date: Jul 2026 --> Jul 2027
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells
    29d
    Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (clinicaltrials.gov)
    P3, N=550, Recruiting, Kite, A Gilead Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    30d
    MB-CART2019.1 in Refractory Multiple Sclerosis (clinicaltrials.gov)
    P1/2, N=26, Recruiting, Miltenyi Biomedicine GmbH | Not yet recruiting --> Recruiting | Trial completion date: Dec 2030 --> Aug 2030 | Trial primary completion date: Feb 2030 --> Aug 2030
    Enrollment open • Trial completion date • Trial primary completion date
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    1m
    P-CD19CD20-ALLO1-001: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Poseida Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    RG6540 • rimiducid (AP1903)
    1m
    FRONTIER: Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Miltenyi Biomedicine GmbH
    New P2 trial
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1)
    |
    TP53 mutation • Chr t(11;14)
    |
    cyclophosphamide • fludarabine IV • zamtocabtagene autoleucel (MB-CART2019.1)
    1m
    RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    1m
    DALY 2-EU: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (clinicaltrials.gov)
    P2, N=213, Recruiting, Miltenyi Biomedicine GmbH | Active, not recruiting --> Recruiting | N=45 --> 213
    Enrollment open • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)
    1m
    KT-US-499-0150: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=25, Active, not recruiting, Kite, A Gilead Company | Recruiting --> Active, not recruiting | N=14 --> 25 | Active, not recruiting --> Recruiting
    Enrollment closed • Enrollment open • Enrollment change
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CSF2 (Colony stimulating factor 2) • IL15 (Interleukin 15) • IL1R1 (Interleukin 1 receptor, type I) • IL7 (Interleukin 7)
    |
    cyclophosphamide • fludarabine IV • KITE-363
    2ms
    INVISE: A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Kite, A Gilead Company | Recruiting --> Active, not recruiting | N=34 --> 10 | Trial completion date: Mar 2031 --> Jul 2026 | Trial primary completion date: Mar 2028 --> Jul 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)